TAC — A New Standard in Adjuvant Therapy for Breast Cancer?
- 2 June 2005
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (22), 2346-2348
- https://doi.org/10.1056/NEJMe058056
Abstract
Editorial from The New England Journal of Medicine — TAC — A New Standard in Adjuvant Therapy for Breast Cancer?Keywords
This publication has 6 references indexed in Scilit:
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Improving patient care through molecular diagnosticsSeminars in Oncology, 2004
- Advances in Screening, Diagnosis, and Treatment of Breast CancerMayo Clinic Proceedings, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast CancerJournal of Clinical Oncology, 2003
- Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated?Current Oncology Reports, 2003